Every finding on record at Azorna Healthcare Tucson LLC

It is required that the documented comprehensive assessment includes a drug profile that contains the patient's current prescription and over-the-counter (OTC) drug. This standard was not met as evidenced by interview and observation. In 2 of 3 (67%) home visits observed revealed that the agency did not ensure the comprehensive assessment included a drug profile that contained the patient's current prescription(s) and OTC drug(s). Home Visit #1: The home visit was completed on 07/28/2025 with the Director of Clinical Services (DCS) (Personnel #1) at the assisted living facility (ALF). The hospice medication profile contained Senna 5mg PO daily. It was determined after comparing the hospice medication profile dated 07/28/2025 to the facility MAR that the facility MAR lacked evidence of "Senna 5 mg PO daily.” This medication was ordered by the hospice physician on 05/08/2025. The DCS (Personnel #1) confirmed in an Interview during the patient visit on 07/28/2025 that "Senna 5 mg PO daily" was missing from the facility MAR. HOME VISIT #3: The home visit was completed on 07/29/2025 with the Chaplain (Personnel #3). During the visit, a medication review was completed by the site visitor with the patient's spouse. The spouse presented all the medication bottles she currently administered to the patient including a bottle labeled Ramipril 5mg PO every day. It was determined after comparing the hospice medication profile dated 07/28/2025 to the medication bottles that the hospice medication profile did not include "Ramipril 5 mg PO every day.” The patient’s spouse said the medication was not paid for by the hospice and they got it from their own pharmacy. The Administrator/Alternate Director of Clinical Services (DCS) and Alternate Administrator/DCS stated in an interview on 07/30/2025 that the medication was supposed to be reconciled every visit.

It is required that the comprehensive assessment includes an initial bereavement assessment of the needs of the patient's family and other individuals, focusing on the social, spiritual, and cultural factors that may impact their ability to cope with the patient's death. This standard was not met as evidenced by clinical record review and interview. In 1 of 14 (7%) clinical records reviewed revealed the agency did not ensure the comprehensive assessment included an initial bereavement assessment of the needs of the patient's family and other individuals, focusing on the social, spiritual, and cultural factors that may impact their ability to cope with the patient's death. CLINICAL RECORD 2: The patient elected the hospice benefit on 06/24/2025. The clinical record lacked evidence of a completed initial bereavement assessment as part of the comprehensive assessment. The Administrator/Alternate Director of Clinical Services (DCS) and Alternate Administrator/DCS stated in an interview on 07/30/2025 that the agency did not ensure that the comprehensive assessment included an initial bereavement assessment of the needs of the patient's family and other individuals, focusing on the social, spiritual, and cultural factors that may impact their ability to cope with the patient's death.